Jump to content

Bufotenin

From Wikipedia, the free encyclopedia
(Redirected from 5-HO-DMT)
Bufotenin
Clinical data
Other namesBufotenine; 5-Hydroxy-N,N-dimethyltryptamine; 5-HO-DMT; 5-OH-DMT; N,N-Dimethyl-5-hydroxytryptamine; N,N-Dimethylserotonin; Dimethylserotonin; Dimethyl-5-HT; Cebilcin; Mappine
Routes of
administration		Oral, intravenous
ATC code
  • None
Legal status
Legal status
Identifiers
  • 3-[2-(Dimethylamino)ethyl]-1H-indol-5-ol
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.006.971 Edit this at Wikidata
Chemical and physical data
FormulaC12H16N2O
Molar mass204.273 g·mol−1
3D model (JSmol)
Melting point146 to 147 °C (295 to 297 °F)
Boiling point320 °C (608 °F)
  • CN(C)CCc1c[nH]c2ccc(O)cc12
  • InChI=1S/C12H16N2O/c1-14(2)6-5-9-8-13-12-4-3-10(15)7-11(9)12/h3-4,7-8,13,15H,5-6H2,1-2H3 checkY
  • Key:VTTONGPRPXSUTJ-UHFFFAOYSA-N checkY
  (verify)

Bufotenin, also known as dimethylserotonin or as 5-hydroxy-N,N-dimethyltryptamine (5-HO-DMT), is a tryptamine derivative, more specifically, a dimethyltryptamine (DMT) analogue, related to the neurotransmitter serotonin. It is an alkaloid found in some species of mushrooms, plants and toads, especially the skin. It is also found naturally in the human body in small amounts.[1][2][3]

The name bufotenin originates from the toad genus Bufo, which includes several species of psychoactive toads, most notably Incilius alvarius, that secrete bufotoxins from their parotoid glands.[4] Bufotenin is similar in chemical structure to the psychedelics psilocin (4-HO-DMT), 5-MeO-DMT and DMT, chemicals which also occur in some of the same fungus, plant and animal species as bufotenin.

Nomenclature

[edit]

Bufotenin (bufotenine) is also known by the names 5-hydroxy-N,N-dimethyltryptamine (5-HO-DMT), N,N-dimethyl-5-hydroxytryptamine, dimethylserotonin, and mappine, among others.[5]

History

[edit]

Bufotenin was isolated from toad skin, and named by the Austrian chemist Handovsky at the University of Prague during World War I.[6] The structure of bufotenine was confirmed in 1934 by Heinrich Wieland's laboratory in Munich, and the first reported synthesis of bufotenine was by Toshio Hoshino and Kenya Shimodaira in 1935.[7]

Sources

[edit]

Toads

[edit]

Bufotenin is found in the skin and eggs of several species of toads belonging to the genus Bufo, but is most concentrated in the Colorado River toad (formerly Bufo alvarius, now Incilius alvarius), the only toad species with enough bufotenin for a psychoactive effect. Extracts of toad toxin, containing bufotenin and other bioactive compounds, have been used in some traditional medicines such as ch'an su (probably derived from Bufo gargarizans), which has been used medicinally for centuries in China.[8]

The toad was "recurrently depicted in Mesoamerican art",[9] which some authors have interpreted as indicating that the effects of ingesting Bufo secretions have been known in Mesoamerica for many years; however, others doubt that this art provides sufficient "ethnohistorical evidence" to support the claim.[8]

In addition to bufotenin, Bufo secretions also contain digoxin-like cardiac glycosides, and ingestion of these toxins can be fatal. Ingestion of Bufo toad poison and eggs by humans has resulted in several reported cases of poisoning,[10][11][12] some of which resulted in death. A court case in Spain, involving a physician who dosed people with smoked Mexican Toad poison, one of his customers died after inhaling three doses, instead of the usual of only one, had images of intoxicated with this smoke suffering obvious hypocalcemic hand muscular spasms.[12][13][14]

Reports in the mid-1990s indicated that bufotenin-containing toad secretions had appeared as a street drug, supposedly but in fact not an aphrodisiac,[15] ingested orally in the form of ch'an su,[12] or as a psychedelic, by smoking or orally ingesting Bufo toad secretions or dried Bufo skins. The use of chan'su and love stone (a related toad skin preparation used as an aphrodisiac in the West Indies) has resulted in several cases of poisoning and at least one death.[12][16] The practice of orally ingesting toad poison has been referred to in popular culture and in the scientific literature as toad licking and has drawn media attention.[17][18] Albert Most, founder of the defunct Church of the Toad of Light and a proponent of spiritual use of Bufo alvarius toxin, published a booklet in 1983 titled Bufo alvarius: The Psychedelic Toad of the Sonoran Desert[19][20] which explained how to extract and smoke the secretions.

Bufotenin is also present in the skin secretion of three arboreal hylid frogs of the genus Osteocephalus (Osteocephalus taurinus, Osteocephalus oophagus, and Osteocephalus langsdorfii) from the Amazon and Atlantic rain forests.[21]

Anadenanthera seeds

[edit]
Yopo seeds from the perennial Anadenanthera Peregrina tree have a long history of entheogenic use and induce a short but distinct psychedelic experience.

Bufotenin is a constituent of the seeds of Anadenanthera colubrina and Anadenanthera peregrina trees. Anadenanthera seeds have been used as an ingredient in psychedelic snuff preparations by indigenous cultures of the Caribbean, Central and South America since pre-Columbian times.[22][23][24] The oldest archaeological evidence of use of Anadenanthera beans is over 4,000 years old.[23]

Other sources

[edit]

Bufotenin has been identified as a component in the latex of the takini (Brosimum acutifolium) tree, which is used as a psychedelic by South American shamans,[25] and in the seeds of Mucuna pruriens.[26] Bufotenin has also been identified in Amanita muscaria, Amanita citrina, A. porphyria, and A. tomentella.[27][28]

Humans

[edit]

Bufotenin occurs in trace amounts in the human body.[1][2][3][29] It can be biosynthesized from serotonin by indolethylamine N-methyltransferase (INMT) enzymes.[1][29]

Association with schizophrenia and other mental disorders

[edit]

A study conducted in the late 1960s reported the detection of bufotenin in the urine of schizophrenic subjects;[30] however, subsequent research failed to confirm these findings until 2010.[31][32][33][34][35]

Studies have detected endogenous bufotenin in urine specimens from individuals with other psychiatric disorders,[36] such as infant autistic patients.[37] Another study indicated that paranoid violent offenders or those who committed violent behaviour towards family members have higher bufotenin levels in their urine than other violent offenders.[38]

A 2010 study utilized a mass spectrometry approach to detect levels of bufotenin in the urine of individuals with severe autism spectrum disorder (ASD), schizophrenia, and asymptomatic subjects. Their results indicate significantly higher levels of bufotenin in the urine of the ASD and schizophrenic groups when compared to asymptomatic individuals.[35]

Pharmacology

[edit]

Pharmacodynamics

[edit]

Bufotenin is an analogue of the monoamine neurotransmitter serotonin.[39][40] Similarly to serotonin and related compounds like dimethyltryptamine (DMT), bufotenin is a potent agonist of the serotonin 5-HT2A and 5-HT2C receptors.[39][40] It is also known to bind with high affinity to other serotonin receptors, including the serotonin 5-HT1A, 5-HT1B, 5-HT1D, and 5-HT3 receptors, and is likely to be a serotonin 5-HT4 receptor agonist.[2][40] In addition to its serotonin receptor agonism, bufotenin is a potent serotonin releasing agent with an EC50Tooltip half-maximal effective concentration value of 30.5 nM.[41]

Bufotenin has greatly reduced capacity to cross the blood–brain barrier due to its relatively high hydrophilicity and hence shows prominent peripheral selectivity.[39] As a result, bufotenin has a much greater ratio of peripheral activity to central effect.[39] Studies in humans and animals have found a relative lack of psychedelic effects with bufotenin.[39] However, other studies in humans have reported that the compound can produce psychedelic effects.[42][43] In any case, bufotenin has often been reported to produce pronounced peripheral serotonergic effects.[39][2] These have included cardiovascular, gastrointestinal, and other effects, among them increased respiratory rate, chest heaviness, purpling of the head and neck skin (intense skin flushing), nausea, vomiting, and retching.[39][2] It is possible that in addition to its limited central permeation, the peripheral effects of bufotenin have served to mask its central and hallucinogenic effects.[39]

In contrast to peripheral administration, intracerebroventricular injection of bufotenin in animals produces robust psychedelic-like behavioral effects similar to those of other serotonergic psychedelics like 5-MeO-DMT.[39] In addition, 5-MeO-DMT, the O-methylated analogue of bufotenin, which has much greater lipophilicity, is readily able to cross the blood–brain barrier and produce psychedelic effects.[39] Bufotenin prodrug esters, with greater lipophilicity than bufotenin itself, like O-acetylbufotenin and O-pivalylbufotenin, have also shown psychedelic-like effects in animals.[39][44][45]

Psilocin (4-hydroxy-N,N-dimethyltryptamine) is a positional isomer of bufotenin and might be expected to have similarly limited lipophilicity and blood–brain permeability.[39] However, psilocin appears to form a pseudo-ring system wherein its hydroxyl group and amine interact through ionic bonding.[39][40] This in turn results in psilocin being much less polar, more lipophilic, and more able to cross the blood–brain barrier and exert central actions than it would be otherwise.[39][40] In contrast, bufotenin is not able to achieve this pseudo-ring system.[39][40] Accordingly, the experimentally observed partition coefficient of psilocin and 5-MeO-DMT have been reported to both be 3.30, whereas that of bufotenin was reported to be 0.06.[39] A minimum partition coefficient of 1.40 has been proposed for hallucinogenic effects in vivo and an optimal value of 3.14 has been suggested.[39] In any case, bufotenin does still appear to show minor central permeability and some capacity for psychoactive effects.[39][40]

Effects in humans

[edit]
Fabing & Hawkins (1955)
[edit]

In 1955, Fabing and Hawkins administered bufotenin intravenously at doses of up to 16 mg to prison inmates at Ohio State Penitentiary.[46] A toxic effect causing purpling of the face was seen in these tests.

A subject given 1 mg reported "a tight feeling in the chest" and prickling "as if he had been jabbed by needles." This was accompanied by a "fleeting sensation of pain in both thighs and a mild nausea."[46]

Another subject given 2 mg reported "tightness in his throat." He had tightness in the stomach, tingling in pretibial areas, and developed a purplish hue in the face indicating blood circulation problems. He vomited after 3 minutes.[46]

Another subject given 4 mg complained of "chest oppression" and that "a load is pressing down from above and my body feels heavy." The subject also reported "numbness of the entire body" and "a pleasant Martini feeling-my body is taking charge of my mind." The subject reported he saw red spots passing before his eyes and red-purple spots on the floor, and the floor seemed very close to his face. Within 2 minutes these visual effects were gone, and replaced by a yellow haze, as if he were looking through a lens filter.[46]

Fabing and Hawkins commented that bufotenin's psychedelic effects were "reminiscent of LSD and mescaline but develop and disappear more quickly, indicating rapid central action and rapid degradation of the drug".[citation needed]

Isbell (1956)
[edit]

In 1956, Harris Isbell at the Public Health Service Hospital in Lexington, Kentucky, experimented with bufotenin as a snuff. He reported "no subjective or objective effects were observed after spraying with as much as 40 mg bufotenine"; however, subjects who received 10–12 mg by intramuscular injection reported "elements of visual hallucinations consisting of a play of colors, lights, and patterns."[6]

Turner & Merlis (1959)
[edit]

Turner and Merlis (1959)[47] experimented with intravenous administration of bufotenin (as the water-soluble creatinine sulfate salt) to schizophrenics at a New York state hospital. They reported that when one subject received 10 mg during a 50-second interval, "the peripheral nervous system effects were extreme: at 17 seconds, flushing of the face, at 22 seconds, maximal inhalation, followed by maximal hyperventilation for about 2 minutes, during which the patient was unresponsive to stimuli; her face was plum-colored." Finally, Turner and Merlis reported:

on one occasion, which essentially terminated our study, a patient who received 40 mg intramuscularly, suddenly developed an extremely rapid heart rate; no pulse could be obtained; no blood pressure measured. There seemed to have been an onset of auricular fibrillation . . . extreme cyanosis developed. Massage over the heart was vigorously executed and the pulse returned to normal . . . shortly thereafter the patient, still cyanotic, sat up saying: "Take that away. I don't like them."

After pushing doses to the morally admissible limit without producing visuals, Turner and Merlis conservatively concluded: "We must reject bufotenine . . . as capable of producing the acute phase of Cohoba intoxication."[6]

McLeod and Sitaram (1985)
[edit]

A 1985 study by McLeod and Sitaram in humans reported that bufotenin administered intranasally at a dose of 1–16 mg had no effect, other than intense local irritation. When given intravenously at low doses (2–4 mg), bufotenin oxalate caused anxiety but no other effects; however, a dose of 8 mg resulted in profound emotional and perceptual changes, involving extreme anxiety, a sense of imminent death, and visual disturbance associated with color reversal and distortion, and intense flushing of the cheeks and forehead.[48]

Ott (2001)
[edit]

In 2001, ethnobotanist Jonathan Ott published the results of a study in which he self-administered free base bufotenin via insufflation (5–100 mg), sublingually (50 mg), intrarectally (30 mg), orally (100 mg) and via vaporization (2–8 mg).[43] Ott reported "visionary effects" of intranasal bufotenin and that the "visionary threshold dose" by this route was 40 mg, with smaller doses eliciting perceptibly psychoactive effects. He reported that "intranasal bufotenine is throughout quite physically relaxing; in no case was there facial rubescence, nor any discomfort nor disesteeming side effects".

At 100 mg, effects began within 5 minutes, peaked at 35–40 minutes, and lasted up to 90 minutes. Higher doses produced effects that were described as psychedelic, such as "swirling, colored patterns typical of tryptamines, tending toward the arabesque". Free base bufotenin taken sublingually was found to be identical to intranasal use. The potency, duration, and psychedelic action was the same. Ott found vaporized free base bufotenin active from 2–8 mg with 8 mg producing "ring-like, swirling, colored patterns with eyes closed". He noted that the visual effects of insufflated bufotenin were verified by one colleague, and those of vaporized bufotenin by several volunteers.

Ott concluded that free base bufotenin taken intranasally and sublingually produced effects similar to those of Yopo without the toxic peripheral symptoms, such as facial flushing, observed in other studies in which the drug was administered intravenously.

Lethal dose

[edit]

The acute toxicity (LD50) of bufotenin in rodents has been estimated at 200 to 300 mg/kg. Death occurs by respiratory arrest.[22] In April 2017, a South Korean man died of bufotenin poisoning after consuming toads that had been mistaken for edible Asian bullfrogs,[49] while in Dec. 2019, five Taiwanese men became ill and one man died after eating Central Formosa toads that they mistook for frogs.[50]

Pharmacokinetics

[edit]

Bufotenin has been reported to undergo a strong first-pass effect[2] and to not be orally active.[39] This is in contrast to its positional isomer psilocin, which is thought to form a pseudo-ring system that limits its susceptibility to metabolism by monoamine oxidase (MAO).[39] However, bufotenin actually does show oral activity if sufficiently high doses are taken.[2] About 10-fold higher doses of bufotenin seem to be required orally compared to parenterally for effects.[2]

In rats, subcutaneously administered bufotenin (1–100 μg/kg) distributes mainly to the lungs, heart, and blood, and to a much lesser extent, the brain (hypothalamus, brain stem, striatum, and cerebral cortex), and liver. It reaches peak concentrations at one hour and is nearly eliminated within 8 hours.[51] In humans, intravenous administration of bufotenin results in excretion of (70%) of injected drug in the form of 5-HIAA, an endogenous metabolite of serotonin, while roughly 4% is eliminated unmetabolized in the urine. Orally administered bufotenin undergoes extensive first-pass metabolism by the enzyme monoamine oxidase.

Chemistry

[edit]

Bufotenin, also known as 5-hydroxy-N,N-dimethyltryptamine (5-HO-DMT), is a substituted tryptamine and a derivative of dimethyltryptamine (DMT; N,N-dimethyltryptamine) and serotonin (5-hydroxytryptamine; 5-HT).

The predicted log P of bufotenin ranges from 0.89 to 2.04.[52][53][54] For comparison, the predicted log P of DMT is 2.06 to 2.5[55][56][57] and of serotonin is 0.2 to 0.56.[58][59][60]

Analogues and derivatives

[edit]

Some analogues and derivatives of bufotenin (5-HO-DMT), aside from serotonin and DMT, include psilocin (4-HO-DMT) (a positional isomer), 5-MeO-DMT (O-methylbufotenin), O-acetylbufotenine, O-pivalylbufotenine, bufotenidine (N-methylbufotenin), 5-HO-DiPT, and α-methylserotonin, among others.

[edit]

Australia

[edit]

Bufotenin is classified as a Schedule I controlled substance according to the Criminal Code Regulations of the Government of the Commonwealth of Australia.[61] It is also listed as a Schedule 9 substance under the Poisons Standard (October 2015).[62] A schedule 9 drug is outlined in the Poisons Act 1964 as "Substances which may be abused or misused, the manufacture, possession, sale or use of which should be prohibited by law except when required for medical or scientific research, or for analytical, teaching or training purposes with approval of the CEO."[63]

Under the Misuse of Drugs Act 1981 6.0 grams (0.21 oz) is determined to be enough for court of trial and 2.0 grams (0.071 oz) is considered intent to sell and supply.[64]

United Kingdom

[edit]

In the United Kingdom, bufotenin is a Class A drug under the 1971 Misuse of Drugs Act.

United States

[edit]

Bufotenin (DEA Drug Code 7403) is regulated as a Schedule I drug by the Drug Enforcement Administration at the federal level in the United States and is therefore illegal to buy, possess, and sell.[65]

Sweden

[edit]

Sweden's public health agency suggested classifying Bufotenin as a hazardous substance, on May 15, 2019.[66]

See also

[edit]

References

[edit]
  1. ^ a b c Barker SA, McIlhenny EH, Strassman R (2012). "A critical review of reports of endogenous psychedelic N, N-dimethyltryptamines in humans: 1955-2010". Drug Test Anal. 4 (7–8): 617–635. doi:10.1002/dta.422. PMID 22371425.
  2. ^ a b c d e f g h Neumann J, Dhein S, Kirchhefer U, Hofmann B, Gergs U (2024). "Effects of hallucinogenic drugs on the human heart". Front Pharmacol. 15: 1334218. doi:10.3389/fphar.2024.1334218. PMC 10869618. PMID 38370480.
  3. ^ a b Kärkkäinen J, Forsström T, Tornaeus J, Wähälä K, Kiuru P, Honkanen A, Stenman UH, Turpeinen U, Hesso A (2005). "Potentially hallucinogenic 5-hydroxytryptamine receptor ligands bufotenine and dimethyltryptamine in blood and tissues". Scand J Clin Lab Invest. 65 (3): 189–199. doi:10.1080/00365510510013604. PMID 16095048.
  4. ^ Bufo Alvarius. AmphibiaWeb. Accessed on May 6, 2007.
  5. ^ "DEA Drug Scheduling". U.S. Drug Enforcement Administration. Archived from the original on 2008-10-20. Retrieved 2007-08-11.
  6. ^ a b c Chilton WS, Bigwood J, Jensen RE (1979). "Psilocin, bufotenine and serotonin: historical and biosynthetic observations". Journal of Psychedelic Drugs. 11 (1–2): 61–69. doi:10.1080/02791072.1979.10472093. PMID 392119.
  7. ^ Hoshino T, Shimodaira K (1935). "Synthese des Bufotenins und über 3-Methyl-3-β-oxyäthyl-indolenin. Synthesen in der Indol-Gruppe. XIV". Justus Liebig's Annalen der Chemie. 520 (1): 19–30. doi:10.1002/jlac.19355200104.
  8. ^ a b Davis W, Weil A (1992). "Identity of a New World Psychoactive Toad". Ancient Mesoamerica. 3: 51–9. doi:10.1017/s0956536100002297. S2CID 162875250.
  9. ^ Yao B, Wang L, Wang H, Bao J, Li Q, Yu F, et al. (April 2021). "Seven interferon gamma response genes serve as a prognostic risk signature that correlates with immune infiltration in lung adenocarcinoma". Aging. 13 (8): 11381–11410. doi:10.1086/202831. PMC 8109098. PMID 33839701. S2CID 143698915.
  10. ^ Hitt M, Ettinger DD (June 1986). "Toad toxicity". The New England Journal of Medicine. 314 (23): 1517–1518. doi:10.1056/NEJM198606053142320. PMID 3702971.
  11. ^ Ragonesi DL (1990). "The boy who was all hopped up". Contemporary Pediatrics. 7: 91–4.
  12. ^ a b c d Brubacher JR, Ravikumar PR, Bania T, Heller MB, Hoffman RS (November 1996). "Treatment of toad toxin poisoning with digoxin-specific Fab fragments". Chest. 110 (5): 1282–1288. doi:10.1378/chest.110.5.1282. PMID 8915235.
  13. ^ Gowda RM, Cohen RA, Khan IA (April 2003). "Toad venom poisoning: resemblance to digoxin toxicity and therapeutic implications". Heart. 89 (4): 14e–14. doi:10.1136/heart.89.4.e14. PMC 1769273. PMID 12639891.
  14. ^ Lever, Christopher (2001). The Cane Toad: The History and Ecology of a Successful Colonist. Westbury Academic & Scientific Publishing. ISBN 978-1-84103-006-7.
  15. ^ Rodrigues, R.J. Aphrodisiacs through the Ages: The Discrepancy Between Lovers' Aspirations and Their Desires. ehealthstrategies.com
  16. ^ Centers for Disease Control and Prevention (CDC) (November 1995). "Deaths associated with a purported aphrodisiac--New York City, February 1993-May 1995". MMWR. Morbidity and Mortality Weekly Report. 44 (46): 853–5, 861. PMID 7476839.
  17. ^ The Dog Who Loved to Suck on Toads. NPR. Accessed on May 6, 2007.
  18. ^ Psychoactive toad: Cultural references
  19. ^ Most, A. "Bufo avlarius: The Psychedelic Toad of the Sonoran Desert". erowid.org. Retrieved 2007-08-12.
  20. ^ How 'bout them toad suckers? Ain't they clods? Archived September 28, 2011, at the Wayback Machine Smoky Mountain News. Accessed on May 6, 2007
  21. ^ Costa TO, Morales RA, Brito JP, Gordo M, Pinto AC, Bloch C (September 2005). "Occurrence of bufotenin in the Osteocephalus genus (Anura: Hylidae)". Toxicon. 46 (4): 371–375. Bibcode:2005Txcn...46..371C. doi:10.1016/j.toxicon.2005.02.006. PMID 16054186.
  22. ^ a b Repke DB, Torres CM (2006). Anadenanthera: visionary plant of ancient South America. New York: Haworth Herbal Press. ISBN 978-0-7890-2642-2.
  23. ^ a b Pochettino ML, Cortella AR, Ruiz M (1999). "Hallucinogenic Snuff from Northwestern Argentina: Microscopical Identification of Anadenanthera colubrina var. cebil (Fabaceae) in Powdered Archaeological Material". Economic Botany. 53 (2): 127–132. Bibcode:1999EcBot..53..127P. doi:10.1007/BF02866491. ISSN 0013-0001. JSTOR 4256172. S2CID 13153575.
  24. ^ Miller MJ, Albarracin-Jordan J, Moore C, Capriles JM (June 2019). "Chemical evidence for the use of multiple psychotropic plants in a 1,000-year-old ritual bundle from South America". Proceedings of the National Academy of Sciences of the United States of America. 116 (23): 11207–11212. Bibcode:2019PNAS..11611207M. doi:10.1073/pnas.1902174116. PMC 6561276. PMID 31061128.
  25. ^ Moretti C, Gaillard Y, Grenand P, Bévalot F, Prévosto JM (June 2006). "Identification of 5-hydroxy-tryptamine (bufotenine) in takini (Brosimumacutifolium Huber subsp. acutifolium C.C. Berg, Moraceae), a shamanic potion used in the Guiana Plateau". Journal of Ethnopharmacology. 106 (2): 198–202. doi:10.1016/j.jep.2005.12.022. PMID 16455218.
  26. ^ Chamakura RP (1994). "Bufotenine—a hallucinogen in ancient snuff powders of South America and a drug of abuse on the streets of New York City". Forensic Sci Rev. 6 (1): 2–18.
  27. ^ Rumack BH, Spoerke DG (1994). Handbook of Mushroom Poisoning: Diagnosis and Treatment. CRC Press. p. 208. ISBN 978-0849301940.
  28. ^ Buck, Robert W. (1963-08-24). "Toxicity of Amanita muscaria". JAMA. 185 (8): 663–664. doi:10.1001/jama.1963.03060080059020. ISSN 0098-7484. PMID 14016551.
  29. ^ a b Jiménez JH, Bouso JC (August 2022). "Significance of mammalian N, N-dimethyltryptamine (DMT): A 60-year-old debate". J Psychopharmacol. 36 (8): 905–919. doi:10.1177/02698811221104054. PMID 35695604.
  30. ^ Faurbye A, Pind K (November 1968). "Occurrence of bufotenin in the urine of schizophrenic patients and normal persons". Nature. 220 (5166): 489. Bibcode:1968Natur.220..489F. doi:10.1038/220489a0. PMID 5686166. S2CID 4192320.
  31. ^ Siegel M (October 1965). "A sensitive method for the detection of n,n-dimethylserotonin (bufotenin) in urine; failure to demonstrate its presence in the urine of schizophrenic and normal subjects". Journal of Psychiatric Research. 3 (3): 205–211. doi:10.1016/0022-3956(65)90030-0. PMID 5860629.
  32. ^ Pomilio AB, Vitale AA, Ciprian-Ollivier J, Cetkovich-Bakmas M, Gómez R, Vázquez G (April 1999). "Ayahoasca: an experimental psychosis that mirrors the transmethylation hypothesis of schizophrenia". Journal of Ethnopharmacology. 65 (1): 29–51. doi:10.1016/S0378-8741(98)00163-9. PMID 10350367.
  33. ^ Ciprian-Ollivier J, Cetkovich-Bakmas MG (December 1997). "Altered consciousness states and endogenous psychoses: a common molecular pathway?". Schizophrenia Research. 28 (2–3): 257–265. doi:10.1016/S0920-9964(97)00116-3. PMID 9468359. S2CID 20830063.
  34. ^ Carpenter WT, Fink EB, Narasimhachari N, Himwich HE (October 1975). "A test of the transmethylation hypothesis in acute schizophrenic patients". The American Journal of Psychiatry. 132 (10): 1067–1071. doi:10.1176/ajp.132.10.1067. PMID 1058643.
  35. ^ a b Emanuele E, Colombo R, Martinelli V, Brondino N, Marini M, Boso M, et al. (2010). "Elevated urine levels of bufotenine in patients with autistic spectrum disorders and schizophrenia". Neuro Endocrinology Letters. 31 (1): 117–121. PMID 20150873.
  36. ^ Takeda N, Ikeda R, Ohba K, Kondo M (November 1995). "Bufotenine reconsidered as a diagnostic indicator of psychiatric disorders". NeuroReport. 6 (17): 2378–2380. doi:10.1097/00001756-199511270-00024. PMID 8747157.
  37. ^ Takeda N (February 1994). "Serotonin-degradative pathways in the toad (Bufo bufo japonicus) brain: clues to the pharmacological analysis of human psychiatric disorders". Comparative Biochemistry and Physiology Part C: Pharmacology, Toxicology and Endocrinology. 107 (2): 275–281. doi:10.1016/1367-8280(94)90051-5. PMID 7749594.
  38. ^ Räisänen MJ, Virkkunen M, Huttunen MO, Furman B, Kärkkäinen J (September 1984). "Increased urinary excretion of bufotenin by violent offenders with paranoid symptoms and family violence". Lancet. 2 (8404): 700–701. doi:10.1016/S0140-6736(84)91263-7. PMID 6147728. S2CID 33258299.
  39. ^ a b c d e f g h i j k l m n o p q r s t McBride MC (2000). "Bufotenine: toward an understanding of possible psychoactive mechanisms". J Psychoactive Drugs. 32 (3): 321–331. doi:10.1080/02791072.2000.10400456. PMID 11061684.
  40. ^ a b c d e f g Plazas E, Faraone N (February 2023). "Indole Alkaloids from Psychoactive Mushrooms: Chemical and Pharmacological Potential as Psychotherapeutic Agents". Biomedicines. 11 (2): 461. doi:10.3390/biomedicines11020461. PMC 9953455. PMID 36830997.
  41. ^ Blough BE, Landavazo A, Decker AM, Partilla JS, Baumann MH, Rothman RB (October 2014). "Interaction of psychoactive tryptamines with biogenic amine transporters and serotonin receptor subtypes". Psychopharmacology (Berl). 231 (21): 4135–4144. doi:10.1007/s00213-014-3557-7. PMC 4194234. PMID 24800892.
  42. ^ Shen HW, Jiang XL, Winter JC, Yu AM (October 2010). "Psychedelic 5-methoxy-N,N-dimethyltryptamine: metabolism, pharmacokinetics, drug interactions, and pharmacological actions". Curr Drug Metab. 11 (8): 659–666. doi:10.2174/138920010794233495. PMC 3028383. PMID 20942780.
  43. ^ a b Ott J (2001). "Pharmañopo-psychonautics: human intranasal, sublingual, intrarectal, pulmonary and oral pharmacology of bufotenine". Journal of Psychoactive Drugs. 33 (3): 273–281. doi:10.1080/02791072.2001.10400574. PMID 11718320. S2CID 5877023.
  44. ^ Glennon RA, Gessner PK, Godse DD, Kline BJ (November 1979). "Bufotenine esters". J Med Chem. 22 (11): 1414–1416. doi:10.1021/jm00197a025. PMID 533890.
  45. ^ Gessner PK, Dankova J (1975). "Brain bufotenine from administered acetylbufotenine: Comparison of its tremorgenic activity with that of N,N-dimethyltryptamine and 5-methoxy-N,N-dimethyltryptamine". Pharmacologist. 17: 259.
  46. ^ a b c d Fabing HD, Hawkins JR (May 1956). "Intravenous bufotenine injection in the human being". Science. 123 (3203): 886–887. Bibcode:1956Sci...123..886F. doi:10.1126/science.123.3203.886. PMID 13324106.
  47. ^ Turner WJ, Merlis S (January 1959). "Effect of some indolealkylamines on man". A.M.A. Archives of Neurology and Psychiatry. 81 (1): 121–129. doi:10.1001/archneurpsyc.1959.02340130141020. PMID 13605329.
  48. ^ McLeod WR, Sitaram BR (November 1985). "Bufotenine reconsidered". Acta Psychiatrica Scandinavica. 72 (5): 447–450. doi:10.1111/j.1600-0447.1985.tb02638.x. PMID 4091027. S2CID 9578617.
  49. ^ "South Korean man dies after eating toads". BBC. 21 April 2017.
  50. ^ "Taiwanese dies from eating toads, 5 injured". Taiwan News. 17 December 2019. Retrieved 2019-12-18.
  51. ^ Fuller RW, Snoddy HD, Perry KW (July 1995). "Tissue distribution, metabolism and effects of bufotenine administered to rats". Neuropharmacology. 34 (7): 799–804. doi:10.1016/0028-3908(95)00049-C. PMID 8532147. S2CID 23801665.
  52. ^ "Bufotenine". PubChem. Retrieved 11 September 2024.
  53. ^ "Bufotenine: Uses, Interactions, Mechanism of Action". DrugBank Online. 31 July 2007. Retrieved 12 September 2024.
  54. ^ "BUFOTENINE". ChemSpider. 12 September 2024. Retrieved 12 September 2024.
  55. ^ "Dimethyltryptamine". PubChem. Retrieved 11 September 2024.
  56. ^ "Dimethyltryptamine: Uses, Interactions, Mechanism of Action". DrugBank Online. 31 July 2007. Retrieved 12 September 2024.
  57. ^ "Dimethyltryptamine". ChemSpider. 12 September 2024. Retrieved 12 September 2024.
  58. ^ "Serotonin". PubChem. Retrieved 11 September 2024.
  59. ^ "Serotonin: Uses, Interactions, Mechanism of Action". DrugBank Online. 21 February 2013. Retrieved 12 September 2024.
  60. ^ "Serotonin". ChemSpider. 12 September 2024. Retrieved 12 September 2024.
  61. ^ Criminal Code Regulation 2005 (SL2005-2) (rtf), Australian Capital Territory, May 1, 2005, retrieved 2007-08-12
  62. ^ Poisons Standard October 2015 https://www.comlaw.gov.au/Details/F2015L01534
  63. ^ Poisons Act 1964 Archived 2015-12-22 at the Wayback Machine. slp.wa.gov.au
  64. ^ Misuse of Drugs Act 1981 (2015) Archived 2015-12-22 at the Wayback Machine. slp.wa.gov.au
  65. ^ §1308.11 Schedule I. Archived 2009-08-27 at the Wayback Machine deadiversion.usdoj.gov
  66. ^ "Folkhälsomyndigheten föreslår att 20 ämnen klassas som narkotika eller hälsofarlig vara" (in Swedish). Folkhälsomyndigheten. 15 May 2019. Archived from the original on 20 October 2021. Retrieved 11 November 2019.
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=Bufotenin&oldid=1257882030"